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Rising serum values of nBsubunit human chorionic
gonadotrophin (hCG) in patients with progressive vulvar
carcinomas
HWA de Bruijn, KA ten Hoor, M Krans and AGJ van der Zee
Department of Obstetrics and Gynaecology, University Hospital Groningen, The Netherlands
Summary Elevated serum levels of the 5-subunit of human chorionic gonadotrophin (hCG) were measured in 50% of patients with
locoregional recurrences or progressive vulvar carcinoma (n = 14). At diagnosis of vulvar cancer, however, the incidence of elevated serum
levels was low (5%) in 104 patients. The rising serum levels during progression of disease indicate that the synthesis of the 1-subunit hCG
can be increased in vulvar carcinoma.
Keywords: vulvar cancer; human chorion gonadotrophin; 1-subunit
Vulvar carcinomas are rare, constituting 5% of all gynaecological
malignancies in The Netherlands (Burger et al, 1995). After
radical vulvectomy with inguinofemoral lymphadenectomy and/or
locoregional radiotherapy, patients are followed up by physical
examination. Serum tumours markers have little or no role in the
detection of lymphogenic spread or tumour recurrence and
progression, although the squamous cell carcinoma (SCC) antigen
has been reported to beelevatedin 15-33% ofthepatients (Patsner
and Mann, 1989; Van der Sijde et al, 1989; Rose et al, 1992).
Previously, hCG was detected in the serum of 10% of women
with vulvar carcinoma (Hussa, 1987). hCG is composed of two
subunits, a and ,B, joined non-covalently. Recently, the urinary
excretion of the renal metabolite of the ,B-subunit of hCG, the ,B-
core fragment, was reported to beelevated in 38% ofvulvarcancer
patients and was proposed as a prognostic indicator of poor
survival (Carter et al, 1995). We therefore investigated the pres-
ence ofthe ,B-subunit ofhCG in the serum samples of 104 patients
with vulvar carcinoma.
PATIENTS AND METHODS
All patients with vulvar malignancies in the north of The
Netherlands are referred to the University Hospital of Groningen
for staging and treatment. Patients were staged following the
FIGO system as I (n = 32), II (n = 48), III (n = 21) or IV (n = 3).
Diagnosis was confirmed by histopathology. The standard treat-
ment involved radical vulvectomy with bilateral inguinofemoral
lymphadenectomy. Surgical therapy was completed with loco-
regional radiotherapy if tumour metastases were present in the
inguinofemoral lymph nodes. Seven patients (one stage II patient
in poor general condition and six stage IV) received radiotherapy
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with curative intent, while one stage III patient only received
palliative radiotherapy to the vulva.
During the study period (1986-94), blood samples were drawn
from all patients with gynaecological cancer and the serum was
stored frozen at -80°C. The samples from patients with vulvar
cancer were selected, including samples from patients with newly
diagnosed vulvar cancer (n = 104), from patients after treatment
because of recurrent or progressive disease (n = 14) and from
patients with a complete remission ofmore than 1 year (n = 26).
Serum levels of the 1-subunit of hCG were measured in an
enzyme immunoassay system (Magia 7000, Merck Biotrol
Diagnostics, Chennevieres-les-Louvres, France). Levels were
expressed in jg 1- of the third WHO standard 13-subunit hCG
75/537. The cross-reaction was <0.001% for intact hCG, 0.003%
for luteinizing hormone (LH) and <0.001% forfollicle-stimulating
hormone (FSH). Interassay coefficients ofvariation were 11.1% at
the level of 30 jig 1-l and 21% at the detection limit of 0.02 jg 1-l
(n = 20). In 50 healthy female blood donors, the serum levels of -
subunit hCG were below the detection limit of0.2 ,ug 1-'.
Serum SCC antigen levels were measured using a microparticle
enzyme immunoassay system (IMx, Abbott Diagnostics, Chicago,
IL, USA). The sensitivity was 0.3 ,ug 1-1 and a variation coefficient
of 7.5% was found. The upper limit ofnormal values was defined
as 1.9 jg 1-1, being the 99th centile in a group of 120 healthy
women and 214 women with a complete remission of more than 2
years after completing treatment for stage I or Ila cervical cancer.
Circulating keratin-19 fragments were measured using the CY-FRA
21-1 assay on an automated enzyme immunoassay system (ES 300,
Boehringer Mannheim, Germany). The coefficient of variation
between different assays was 4.4% at the level of 25 jg 1-' and
7.1% at4 jig1-l. The upperlimit ofnormal was defined at 2.2jig 1-',
the 98th centile in a group ofhealthy female blood donors.
RESULTS
At diagnosis, elevated serum levels of 1-subunit hCG were
measured in only 5 of the 104 patients (Table 1). The values
were not related to clinical stage (X' for trend 3.54, P = 0.060).
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Table 1 Serum levels of ,B-subunit hCG at diagnosis of vulvar cancer
Stage Number elevated Serum level
(>0.20 9g I-)Atotal (jgg I-1)
1/32 2.80
11 1/48 0.36
lil 2/21 0.34 and 8.22
IV 1/3 0.34
Total 5/104
The presence of the 5-subunit of hCG could not be detected
(< 0.20 gg l-l) in serum samples from 26 patients with a complete
remission ofmore than 1 year after completion oftreatment.
Rising serum levels were found in 7 of the 14 patients with
recurrentdisease (50%). Levels up to 5.2 ,ug 1-l were found (Figure
1). The seven patients with elevated levels at recurrent disease all
died from vulvar cancer, compared with four from the seven
patients with normal levels. Serum 5-subunit hCG levels, at either
diagnosis or disease recurrence, did not have a significant prog-
nostic value for survival.
Comparison with other serum markers
In the same group, 18% of the patients demonstrated elevated
serum levels of the SCC antigen (>1.9 jg 1-l) at the time of diag-
nosis. In 87 of these patients, the level of circulating keratin-19
fragments was measured, and 19 (22%) demonstrated elevated
serum levels. At progression ofdisease, serum values of the SCC
antigen were raised in 7 ofthe 12 patients investigated (58%).
DISCUSSION
hCG is well documented as a sensitive and specific marker of
trophoblastic disease and tumours of germ cell origin. In addition,
there are numerous reports showing the presence of low but
detectable levels of hCG in a wide range of extragonadal carci-
nomas (Hussa, 1987; Cole 1994). hCG was identified in the cell
membranes ofcultured cancercells, andthe expression ofthehCG
3-subunit gene was documented in all 28 cancer cell lines investi-
gated (Acevedo, 1995). This might indicate that expression of
hCG is a common phenotypic characteristic of cancer. The
measured rising serum levels ofthe ,B-subunit hCG inpatients with
progressive vulvar carcinomas gives support to the observation of
Carter et al (1995), who measured increased urinary excretion of
the 1-core fragment ofhCG in patients with both newly diagnosed
and recurrent vulvar cancer.
At the time of diagnosis of vulvar cancer, however, the 1-
subunit ofhCG is undetectable in the majority ofthe patients, and
hence its usefulness as a serum marker to follow the course of
disease or to identify patients with poor prognosis remains
doubtful. Serum measurements were reported to be less sensitive
than measurement ofthe 13-core fragment ofhCG in urine samples
from patients with ovarian, endometrial and cervical cancer
(Kinugasa et al, 1995). Thus, the 5% incidence of elevated levels
that we measured at diagnosis may even be an underestimate.
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Figure 1 The course of serum values of 3-subunit hCG (IUX-1) in patients
with recurrent disease. The level of 0.2 IU I-' was used as the upper limit
of normal
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